These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 3918912)

  • 1. Antitumor activity and toxicity of serum protein-bound platinum formed from cisplatin.
    Takahashi K; Seki T; Nishikawa K; Minamide S; Iwabuchi M; Ono M; Nagamine S; Horinishi H
    Jpn J Cancer Res; 1985 Jan; 76(1):68-74. PubMed ID: 3918912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
    Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
    Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction of cisplatin nephrotoxicity by procainamide: does the formation of a cisplatin-procainamide complex play a role?
    Viale M; Vannozzi MO; Pastrone I; Mariggiò MA; Zicca A; Cadoni A; Cafaggi S; Tolino G; Lunardi G; Civalleri D; Lindup WE; Esposito M
    J Pharmacol Exp Ther; 2000 Jun; 293(3):829-36. PubMed ID: 10869382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of normal saline on cisplatin pharmacokinetics and antitumor activity in mice bearing P388 leukemia.
    Fulco RA; Vannozzi M; Collecchi P; Merlo F; Parodi B; Civalleri D; Esposito M
    Anticancer Res; 1990; 10(6):1603-10. PubMed ID: 2285232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolism, protein binding and in vivo activity of the oral platinum drug JM216 and its biotransformation products.
    Raynaud FI; Boxall FE; Goddard P; Barnard CF; Murrer BA; Kelland LR
    Anticancer Res; 1996; 16(4A):1857-62. PubMed ID: 8712713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity.
    Marzano C; Bettio F; Baccichetti F; Trevisan A; Giovagnini L; Fregona D
    Chem Biol Interact; 2004 Jun; 148(1-2):37-48. PubMed ID: 15223355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity and nephrotoxicity of a novel platinum complex, [1,3-bis(diphenylphosphino)propane](trans-1-dach)platinum(I I) dinitrate.
    Baek MS; Rho YS; Jung JC; Chang SG; Nomura M; Miyamoto KJ
    Anticancer Res; 1997; 17(2A):955-9. PubMed ID: 9137434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Schedule dependency of orally administered bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) in vivo.
    McKeage MJ; Kelland LR; Boxall FE; Valenti MR; Jones M; Goddard PM; Gwynne J; Harrap KR
    Cancer Res; 1994 Aug; 54(15):4118-22. PubMed ID: 8033145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor activity and biochemical effects of aphidicolin glycinate (NSC 303812) alone and in combination with cisplatin in vivo.
    O'Dwyer PJ; Moyer JD; Suffness M; Harrison SD; Cysyk R; Hamilton TC; Plowman J
    Cancer Res; 1994 Feb; 54(3):724-9. PubMed ID: 8306334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor activity of a new platinum complex, 2-aminomethyl-pyrrolidine (1, 1-cyclobutanedicarboxylato) platinum (II).
    Endoh K; Akamatsu K; Matsumoto T; Morikawa K; Honda M; Mitsui H; Koizumi M; Koizumi K; Matsuno T
    Anticancer Res; 1989; 9(4):987-91. PubMed ID: 2817826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological and preclinical toxicological studies of 1,2-diaminocyclohexane(isocitrato)platinum(II).
    Macquet JP; Cros S; Armand JP
    Cancer Res; 1984 Sep; 44(9):3736-43. PubMed ID: 6540142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis, cytotoxicity and antitumor activity of platinum(II) complexes of cyclopentanecarboxylic acid hydrazide.
    Kushev D; Gorneva G; Taxirov S; Spassovska N; Grancharov K
    Biol Chem; 1999 Nov; 380(11):1287-94. PubMed ID: 10614821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.
    Kelland LR; Abel G; McKeage MJ; Jones M; Goddard PM; Valenti M; Murrer BA; Harrap KR
    Cancer Res; 1993 Jun; 53(11):2581-6. PubMed ID: 8388318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of therapeutic doses of isotopically labeled platinum antitumor agents in the mouse and rat.
    Robins AB; Leach MO
    Cancer Treat Rep; 1983 Mar; 67(3):245-52. PubMed ID: 6682013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro cytotoxicity, pharmacokinetics and ex vivo pharmacodynamics of a new platinum compound, cis-malonato [(4R,5R-4,5-bis(aminomethyl)-1,3-dioxolane-2-spiro-1'-cyclopentane] platinum (II).
    Kim DK; Kim HT; Cho YB; Kim TS; Kim KH; Hong WS
    Anticancer Res; 1996; 16(1):251-6. PubMed ID: 8615617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ascorbato(1,2-diaminocyclohexane):platinum(II) complexes, a new series of water-soluble antitumor drugs.
    Hacker MP; Khokhar AR; Brown DB; McCormack JJ; Krakoff IH
    Cancer Res; 1985 Oct; 45(10):4748-53. PubMed ID: 4040806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tetravalent platinum complexes with ammine/amine carrier ligand configuration: circumvention of platinum resistance in vivo.
    Siddik ZH; Thai G; Yoshida M; Zhang YP; Khokhar AR
    Anticancer Drug Des; 1994 Dec; 9(6):495-509. PubMed ID: 7880375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulatory effect of axial and equatorial ligands on antitumor activities of trans-1R,2R-diaminocyclohexane platinum(IV) complexes.
    Siddik ZH; al-Baker S; Thai G; Khokhar AR
    Anticancer Drug Des; 1994 Apr; 9(2):139-51. PubMed ID: 8166929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low in vivo toxicity of a novel cisplatin-ursodeoxycholic derivative (Bamet-UD2) with enhanced cytostatic activity versus liver tumors.
    Dominguez MF; Macias RI; Izco-Basurko I; de La Fuente A; Pascual MJ; Criado JM; Monte MJ; Yajeya J; Marin JJ
    J Pharmacol Exp Ther; 2001 Jun; 297(3):1106-12. PubMed ID: 11356935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NTP technical report on the toxicity and metabolism studies of chloral hydrate (CAS No. 302-17-0). Administered by gavage to F344/N rats and B6C3F1 mice.
    Beland FA
    Toxic Rep Ser; 1999 Aug; (59):1-66, A1-E7. PubMed ID: 11803702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.